ImmunoPrecise Antibodies Ltd (IPA) concluded trading on Thursday at a closing price of $0.73, with 68.7 million shares of worth about $50.15 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 73.95% during that period and on June 12, 2025 the price saw a gain of about 21.57%. Currently the company’s common shares owned by public are about 45.77M shares, out of which, 39.68M shares are available for trading.
Stock saw a price change of 3.97% in past 5 days and over the past one month there was a price change of 46.86%. Year-to-date (YTD), IPA shares are showing a performance of 77.29% which decreased to -29.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.27 but also hit the highest price of $1.08 during that period. The average intraday trading volume for ImmunoPrecise Antibodies Ltd shares is 1.04 million. The stock is currently trading 27.31% above its 20-day simple moving average (SMA20), while that difference is up 48.92% for SMA50 and it goes to 48.04% higher than SMA200.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) currently have 45.77M outstanding shares and institutions hold larger chunk of about 8.65% of that.
The stock has a current market capitalization of $33.41M and its 3Y-monthly beta is at 0.22. It has posted earnings per share of -$1.13 in the same period. It has Quick Ratio of 2.11 while making debt-to-equity ratio of 0.51. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IPA, volatility over the week remained 12.16% while standing at 7.42% over the month.
Stock’s fiscal year EPS is expected to rise by 41.40% while it is estimated to increase by 82.54% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 02, 2022 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by The Benchmark Company stated ImmunoPrecise Antibodies Ltd (IPA) stock as a Buy in their note to investors on October 25, 2021, suggesting a price target of $12 for the stock.
